At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Carfilzomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)
In Brief
A Phase 2 clinical trial evaluating Carfilzomib for Lung Transplant Rejection. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous immunoglobulins for AMR after lung transplantation and elucidate important clinical and immunologic phenotypes and mechanisms associated with these outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Transplant Rejection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartNov 2015
Primary CompletionNov 2020
Study CompletionJul 2021
TodayJul 2026
First PostedJun 18, 2015
Enrollment StartNov 1, 2015
Primary CompletionNov 9, 2020
Study CompletionJul 26, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.0 years ago
Interventions
Carfilzomibdrug
Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)